Skip to main content
SpringerLink
Log in

Comparative bioavailability study of two haloperidol decanoate containing products

  • Articles
  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

Abstract

In our hospital pharmacy an injectable solution of haloperidol decanoate 141 mg/ml (equivalent to haloperidol 100 mg/ml) in sesame oil was prepared. The aim of this study was to prove bioequivalence of this formulation with the reference product, Haldol Decanoas®. 15 schizophrenic patients, already stabilized with Haldol Decanoas®, were enrolled. Intramuscular injections were given every three weeks in the following doses: 100 mg (1 ×), 200 mg (7 ×) and 300 mg (7 ×). In this open, randomized, cross-over study all patients received four injections of the reference product, and four injections of the test product. Only after the fourth injection of each product (when steady-state levels were reached) a concentration-time profile of haloperidol was established during the dose interval of 21 days. The pharmacokinetic parameters AUC0–21 and Cmax were statistically evaluated. Based on these parameters the conclusion was drawn that both products were bioequivalent. The preparation of this injectable haloperidol decanoate solution in our hospital pharmacy amounts to an annual saving of approximately $39,000.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Beresford R, Ward A. Haloperidol decanoate; a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 1987;33: 31–49.

    PubMed  Google Scholar 

  2. Pakes GE. Haloperidol decanoate in perspective. In: Johnson DAW, editor. Haloperidol decanoate and the treatment of chronic schizophrenia. New York: Adis Press, 1982:108–11.

    Google Scholar 

  3. Reyntjes AJM, Heykants JJP, Woestenborghs RJH, Gelders YG, Aerts TJL. Pharmacokinetics of haloperidol decanoate: a 2-year follow-up. Int Pharmacopsychiat 1982, 17:238–46.

    Google Scholar 

  4. Deberdt R, Elens P, Berghmans W, Heykants J, Woestenborghs R, Driesens F, et al. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiat Scand 1980;62:356–63.

    PubMed  Google Scholar 

  5. Suy E, Woestenborghs R, Heykants J. Bioavailability and clinical effect of two different concentrations of haloperidol decanoate. Curr Ther Res 1982;31:982–91.

    Google Scholar 

  6. Nayak RK, Nair NPV, Doose DR, McCarthy LR, Desiraju RK. Pharmacokinetics of haloperidol and haloperidol decanoate in schizophrenic patients. Clin Pharmacol Ther 1985;37:217.

    Google Scholar 

  7. Nayak RK, Doose DR, Nair NPV. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol 1987;27:144–50.

    PubMed  Google Scholar 

  8. De Cuyper H, Bollen J, Van Praag HM, Verstraeten D. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. Br J Psychiatry 1986;148:560–6.

    PubMed  Google Scholar 

  9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington: American Psychiatric Press, 1987.

    Google Scholar 

  10. Bouma P, Uges DRA. De bepaling van enige xenobiotica in lichaamsvloeistoffen. Praktische analysevoorschriften IV. Haloperidol [Methods for the analysis of some xenobiotics in body fluids. Haloperidol]. Ziekenhuisfarmacie 1987;3(4): 147.

    Google Scholar 

  11. Westlake WJ. Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci 1972;61:1340–1.

    PubMed  Google Scholar 

  12. Westlake WJ. Statistical aspects of comparative bioavailability trials. Biometrics 1979;35:273–80.

    PubMed  Google Scholar 

  13. Rodda BE, Davis RL. Determining the probability of an important difference in bioavailability. Clin Pharmacol Ther 1980;28:247–52.

    PubMed  Google Scholar 

  14. Fluehler H, Hirtz J, Moser HA. An aid to decision-making in bioequivalence assessment. J Pharmacokinet Biopharm 1981;9:235–43.

    PubMed  Google Scholar 

  15. Fluehler H, Grieve AP, Mandallaz D, Mau J, Moser HA. Bayesian approach to bioequivalence assessment: an example. J Pharm Sci 1983;72:1178–81.

    PubMed  Google Scholar 

  16. Hauck WW, Anderson S. A new statistical procedure for testing equivalence in two groups comparative bioavailability trials. J Pharmacokinet Biopharm 1984;12:83–91.

    PubMed  Google Scholar 

  17. Rocke DM. On testing for bioequivalence. Biometrics 1984;40:225–30.

    PubMed  Google Scholar 

  18. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991;324:746–54.

    PubMed  Google Scholar 

  19. Zuidema J, Pieters FAJM, Duchateau GSMJE. Release and absorption rate aspects of intramuscularly injected pharmaceuticals. Int J Pharm 1988;47:1–12.

    Google Scholar 

  20. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657–80.

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. G. van Weringh

    Present address: Pharmacy Department, Andreas Hospital, Theophile de Bockstraat 8, 1058, NR Amsterdam, The Netherlands

Authors and Affiliations

  1. Central Pharmacy of the Haarlem Hospitals, Haarlem, The Netherlands

    G. van Weringh, R. T. M. van der Hoeven & T. Vos

  2. Psychiatric Hospital Amsterdam (PZA-Centrum Oud-West Noord), de Boelelaan 8, 1083, HJ Amsterdam, The Netherlands

    B. J. Komen & R. E. Thieme

Authors
  1. G. van Weringh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. J. Komen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. E. Thieme
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. T. M. van der Hoeven
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Vos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Weringh, G., Komen, B.J., Thieme, R.E. et al. Comparative bioavailability study of two haloperidol decanoate containing products. Pharm World Sci 16, 343–347 (1994). https://doi.org/10.1007/BF02178564

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02178564

Keywords

Search

Navigation